TL;DR: Aetna, a CVS Health company, modified CPB 0767 governing extended ophthalmoscopy coverage, effective December 3, 2025. Billing teams need to confirm ICD-10 diagnosis codes map to the 28 covered indications before submitting CPT 92201 or CPT 92202.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Extended Ophthalmoscopy — CPB 0767 |
| Policy Code | CPB 0767 |
| Change Type | Modified |
| Effective Date | December 3, 2025 |
| Impact Level | High |
| Specialties Affected | Ophthalmology, Retinal Surgery, Optometry, Endocrinology (diabetic retinopathy), Oncology (ocular malignancies) |
| Key Action | Audit all CPT 92201 and 92202 claims to confirm diagnosis codes align with Aetna's 28 covered indications before the December 3, 2025 effective date |
Aetna Extended Ophthalmoscopy Coverage Criteria and Medical Necessity Requirements 2025
The Aetna extended ophthalmoscopy coverage policy under CPB 0767 covers CPT 92201 and CPT 92202 only when routine ophthalmoscopy has already been performed and found abnormal findings. That sequencing requirement is the first place claims fail. If the medical record doesn't document a prior routine ophthalmoscopy — and an abnormal result — your extended ophthalmoscopy billing is exposed.
Aetna defines medical necessity for extended ophthalmoscopy around 28 specific indications. These range from diabetic retinopathy (background and proliferative), macular degeneration, and retinal detachment to choroidal nevus evaluation for malignant transformation, HIV retinopathy, and Vogt-Koyanagi syndrome. High axial length myopia of -6.00 diopters or less (toward -10.00 D) also qualifies. So does blunt eye trauma, retained intraocular foreign bodies, and uncontrolled glaucoma or glaucoma suspect.
The repeat-visit rule matters too. Aetna covers repeat extended ophthalmoscopy only when there's a documented change in signs, symptoms, or condition. Routine monitoring without a documented change won't support medical necessity. Make sure your providers are documenting the specific clinical change that triggered the repeat exam — not just the underlying diagnosis.
Prior authorization requirements are not explicitly enumerated in this policy update, but the medical necessity criteria are tight enough that any claim without a matching covered ICD-10 will face claim denial. Treat the 28-indication list as your de facto prior auth checklist. If the diagnosis doesn't appear on that list, the reimbursement won't follow.
Aetna Extended Ophthalmoscopy Exclusions and Non-Covered Indications
This is where the policy gets specific — and where denials pile up if your billing guidelines aren't updated.
Aetna classifies extended ophthalmoscopy as experimental, investigational, or unproven for a defined list of indications. These aren't edge cases. Several appear regularly in ophthalmology practices.
The full list of excluded indications includes:
| # | Excluded Procedure |
|---|---|
| 1 | Ciliary body cysts |
| 2 | Congenital hypertrophy of the retinal pigment epithelium |
| 3 | Iris nevus |
| 4 | Juvenile xanthogranuloma |
| 5 | Monitoring of fingolimod (Gilenya) therapy |
| 6 | Monitoring methotrexate or tamoxifen therapy |
| 7 | Monitoring patients on checkpoint inhibitors (e.g., ipilimumab, nivolumab) |
| 8 | Neurodegenerative disorders — including Alzheimer's disease, ALS, Friedreich's ataxia, Huntington's disease, Lewy body disease, multiple-system atrophy, Parkinson's disease, and spinal muscular atrophy |
| 9 | Noonan's syndrome |
| 10 | Ophthalmic artery aneurysm |
| 11 | Optic neuritis |
| 12 | Peri-papillary atrophy |
| 13 | Pseudotumor cerebri (orbital pseudotumor) |
| 14 | Retinal angioma |
| 15 | Retinochoroidal coloboma of iris |
| 16 | Screening for retinob… (this item was truncated in the source policy document — see the full exclusion list in Aetna CPB 0767) |
The neurodegenerative disorders exclusion is the one to flag for your medical director. Practices seeing patients with Parkinson's or Alzheimer's who also have concurrent retinal findings need to document the retinal indication specifically — not the neurological condition — to support coverage. Billing 92201 or 92202 against a neurodegenerative disorder ICD-10 as the primary diagnosis will not get paid.
The checkpoint inhibitor exclusion also warrants attention. Oncology practices that co-manage patients on ipilimumab or nivolumab sometimes order extended ophthalmoscopy for ocular toxicity monitoring. Aetna won't cover it for that indication alone.
Coverage Indications at a Glance
| Indication | Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| Diabetic retinopathy (background, proliferative, or retinal vascular occlusion) | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Macular degeneration | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinal detachment (with or without retinal defect) | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinal defects without retinal detachment | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Choroidal nevus — evaluation for malignant transformation | Covered | 92201, 92202 | D31.30–D31.32 applicable |
| Malignant neoplasm of retina or choroid | Covered | 92201, 92202 | C69.20–C69.32 applicable |
| HIV retinopathy | Covered | 92201, 92202 | B20 applicable |
| High axial length myopia (-6.00 D or less, toward -10.00 D) | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Blunt injury to the eye or periorbital structures | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retained intraocular foreign body | Covered | 92201, 92202 | Magnetic or non-magnetic |
| Penetrating wound to orbit with retained foreign body | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Uncontrolled glaucoma or glaucoma suspect | Covered | 92201, 92202 | Optic atrophy with progressive/reversible cause also covered |
| Vitreous hemorrhage or posterior vitreous detachment | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Chorioretinitis, chorioretinal scars, choroidal degeneration/dystrophies | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinopathy of prematurity | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinoschisis and retinal cysts | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinal hemorrhage, ischemia, exudates, hereditary retinal dystrophies, peripheral retinal degeneration | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Retinal edema | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Metamorphopsia | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Sudden or transient visual loss | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Suspected endophthalmitis (severe pain, redness, photophobia, profound vision loss) | Covered | 92201, 92202 | Clinical criteria must be documented |
| Symptoms suggestive of retinal defect | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Systemic disorders associated with retinal pathology | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Posterior scleritis | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| Degenerative disorders of the globe | Covered | 92201, 92202 | Must follow abnormal routine ophthalmoscopy |
| High-risk medication for retinopathy or optic neuropathy | Covered | 92201, 92202 | Distinct from methotrexate/tamoxifen monitoring (excluded) |
| Vogt-Koyanagi syndrome | Covered | 92201, 92202 | Must document bilateral uveitis and associated features |
| Routine ophthalmoscopy with normal findings | Not Covered | 92201, 92202 | Policy explicitly excludes this |
| Iris nevus | Experimental | 92201, 92202 | D31.40–D31.42 map to benign ciliary body neoplasm |
| Checkpoint inhibitor monitoring (ipilimumab, nivolumab) | Experimental | 92201, 92202 | No coverage for ocular toxicity monitoring alone |
| Methotrexate or tamoxifen monitoring | Experimental | 92201, 92202 | Distinct from "high-risk medication" covered indication |
| Fingolimod (Gilenya) therapy monitoring | Experimental | 92201, 92202 | Not covered |
| Neurodegenerative disorders (Alzheimer's, Parkinson's, ALS, and others) | Experimental | 92201, 92202 | Must not be primary diagnosis driver |
| Optic neuritis | Experimental | 92201, 92202 | Not covered |
| Pseudotumor cerebri | Experimental | 92201, 92202 | Not covered |
| Juvenile xanthogranuloma | Experimental | 92201, 92202 | D76.3 applicable but not covered |
| Retinal angioma | Experimental | 92201, 92202 | Not covered |
| Ciliary body cysts | Experimental | 92201, 92202 | Not covered |
| Congenital hypertrophy of retinal pigment epithelium | Experimental | 92201, 92202 | Not covered |
| Noonan's syndrome | Experimental | 92201, 92202 | Not covered |
| Ophthalmic artery aneurysm | Experimental | 92201, 92202 | Not covered |
| Peri-papillary atrophy | Experimental | 92201, 92202 | Not covered |
| Retinochoroidal coloboma of iris | Experimental | 92201, 92202 | Not covered |
| Screening for retinoblastoma in family history patients | Experimental | 92201, 92202 | Not covered |
Aetna Extended Ophthalmoscopy Billing Guidelines and Action Items 2025
The real issue with this coverage policy isn't the covered indications — most are clinically intuitive. The issue is documentation sequencing and diagnosis code precision. Here's what to do before December 3, 2025.
1. Audit your CPT 92201 and CPT 92202 charge capture templates.
Confirm that your charge capture workflow requires a documented routine ophthalmoscopy with abnormal findings before extended ophthalmoscopy is billed. If your EHR templates don't enforce this sequence, claims will go out with missing documentation. That's a claim denial waiting to happen.
2. Build a diagnosis code crosswalk for the 28 covered indications.
Don't leave it to coders to know which ICD-10 codes map to each indication. Build a reference table that links each of Aetna's 28 covered conditions to specific ICD-10-CM codes. The 761-code list in CPB 0767 is your starting point — but you need it organized by clinical indication, not alphabetically.
3. Flag the medication-monitoring distinction immediately.
Two covered-versus-excluded distinctions will trip up your coders. "High-risk medication for retinopathy or optic neuropathy" is covered. "Monitoring methotrexate, tamoxifen, or fingolimod therapy" is explicitly excluded. For patients on medications classified as high-risk for retinopathy or optic neuropathy per the policy, document the retinal or optic nerve risk as the clinical driver for the exam. Talk to your compliance officer if you're unsure how your current documentation handles this line.
4. Update coder education for neurodegenerative disorder patients.
Patients with Parkinson's, Alzheimer's, or ALS may also have unrelated covered retinal conditions. The exclusion only applies when the neurodegenerative disorder is the reason for the exam. If the patient has concurrent diabetic retinopathy or a choroidal nevus, bill to that covered indication. Document clearly why the exam was ordered.
5. Review repeat visit documentation protocols.
Aetna covers repeat extended ophthalmoscopy only when signs, symptoms, or condition have changed. Routine interval monitoring without documented change doesn't meet medical necessity under this policy. Make sure your providers are recording the specific clinical change — not just the date of the next exam — in their notes.
6. Confirm your billing guidelines reflect the effective date of December 3, 2025.
Any claims for CPT 92201 or 92202 with dates of service on or after December 3, 2025 fall under this updated policy. Pull your payer contract terms for Aetna extended ophthalmoscopy billing and confirm there are no plan-level variations that override CPB 0767. If you bill across multiple Aetna plan types (HMO, PPO, self-funded), verify which plans adopt CPB 0767 directly.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Extended Ophthalmoscopy Under CPB 0767
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 92201 | CPT | Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease |
| 92202 | CPT | Ophthalmoscopy, extended; with drawing of optic nerve or macula (e.g., for glaucoma, macular pathology, tumor) with interpretation and report |
Key ICD-10-CM Diagnosis Codes
The full policy lists 761 ICD-10-CM codes. Below are the primary anchor codes by clinical category. Your billing team should map the complete list from the Aetna CPB 0767 source document.
| Code | Description |
|---|---|
| B20 | Human immunodeficiency virus [HIV] disease |
| C69.20 | Malignant neoplasm of retina or choroid |
| C69.21 | Malignant neoplasm of retina or choroid |
| C69.22 | Malignant neoplasm of retina or choroid |
| C69.23 | Malignant neoplasm of retina or choroid |
| C69.24 | Malignant neoplasm of retina or choroid |
| C69.25 | Malignant neoplasm of retina or choroid |
| C69.26 | Malignant neoplasm of retina or choroid |
| C69.27 | Malignant neoplasm of retina or choroid |
| C69.28 | Malignant neoplasm of retina or choroid |
| C69.29 | Malignant neoplasm of retina or choroid |
| C69.30 | Malignant neoplasm of retina or choroid |
| C69.31 | Malignant neoplasm of retina or choroid |
| C69.32 | Malignant neoplasm of retina or choroid |
| D18.09 | Hemangioma of other sites [retina] |
| D31.30 | Benign neoplasm of choroid [evaluation of choroidal nevus for malignant transformation] |
| D31.31 | Benign neoplasm of choroid [evaluation of choroidal nevus for malignant transformation] |
| D31.32 | Benign neoplasm of choroid [evaluation of choroidal nevus for malignant transformation] |
| D31.40 | Benign neoplasm of ciliary body [iris nevus — experimental] |
| D31.41 | Benign neoplasm of ciliary body [iris nevus — experimental] |
| D31.42 | Benign neoplasm of ciliary body [iris nevus — experimental] |
| D57.0 | Sickle-cell disease |
| D57.1 | Sickle-cell disease |
| D76.3 | Other histiocytosis syndromes [juvenile xanthogranuloma — experimental] |
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy |
| E08.3211–E08.3219 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy (various laterality/macular edema variants) |
| E08.3311–E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy (various variants) |
| E08.3411–E08.3419 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy (various variants) |
| E08.3511–E08.3536 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy (various variants) |
| E08.3520–E08.3529 | Diabetes mellitus due to underlying condition with proliferative retinopathy and macular edema variants |
| E08.3530–E08.3536 | Diabetes mellitus due to underlying condition with proliferative retinopathy, stable, various laterality codes |
The full ICD-10-CM list contains 761 codes spanning diabetic retinopathy variants across E08–E13 diabetes categories, retinal disorder codes, glaucoma codes, choroidal codes, and systemic disease codes. Pull the complete list from the Aetna CPB 0767 policy source before updating your charge capture.
Get the Full Picture for CPT 92201
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.